AQXP Aquinox Pharmaceuticals Inc.

13.23
-0.66  -5%
Previous Close 13.89
Open 13.83
Price To book 2.49
Market Cap 310438140
Shares 23,464,712
Volume 86,771
Short Ratio 8.82
Av. Daily Volume 62,379

SEC filingsSee all SEC filings

  1. 8-K - Current report 171013285
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171013280
  3. 8-K - Current report 17831362
  4. 8-K - Current report 17824340
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17824336

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 1Q 2018.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 KINSHIP
Atopic dermatitis (AD)
Phase 2 trail failed - July 2015
AQX-1125 FLAGSHIP
Chronic obstructive pulmonary disease (COPD)
Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).